The Relationship Between Inflammatory Biomarkers and Symptom Distress in Lung Cancer Patients Undergoing Chemotherapy

Hsiu Ling Chou, Tsu Yi Chao, Tsan Chi Chen, Chi Ming Chu, Chen Hsi Hsieh, Chung Tay Yao, Anthony J. Janckila

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

BACKGROUND:: Symptom distress often occurs in lung cancer patients undergoing chemotherapy. However, a biomarker has not been identified to reflect the severity of their symptom distress. OBJECTIVE:: The aim of this study was to investigate the relationship between symptom distress and serum inflammatory biomarkers in lung cancer patients undergoing chemotherapy. METHODS:: A longitudinal, repeated-measures design was used to assess subjective symptoms (fatigue, sleep disturbance, pain, depression, and confusion), serum biomarkers (tartrate-resistant acid phosphatase 5a [TRACP5a], interleukin 6 [IL-6], IL-8, and C-reactive protein), and white blood cells in 62 lung cancer patients recruited from a single medical center at 3 time points: T1 was the baseline, T2 was the eighth day after the first chemotherapy cycle, and T3 was prior to the second cycle. Symptom distress was measured individually by 5 questionnaires (General Fatigue Scale, Pittsburgh Sleep Quality Index, Brief Pain Inventory, Profile of Mood States–Depressive, and Confusion). RESULTS:: The trend of TRACP5a was positively correlated to the trend of the patients’ symptom distress. However, the trends of IL-6 and IL-8 did not correlate. CONCLUSIONS:: Serum TRACP5a was associated with symptom distress in lung cancer patients. Therefore, TRACP5a might be a potential biomarker to assess symptom distress of lung cancer patients undergoing chemotherapy. IMPLICATIONS FOR PRACTICE:: Oncology nurses may be able to apply TRACP5a expression to predict or monitor multiple distress symptoms in lung cancer patients undergoing chemotherapy. Furthermore, nurses can use these study findings to better understand the patients who need more attention to improve their quality of life.

Original languageEnglish
Pages (from-to)E1-E8
JournalCancer Nursing
Volume40
Issue number2
DOIs
Publication statusPublished - 2017

Fingerprint

Lung Neoplasms
Biomarkers
Drug Therapy
Confusion
Interleukin-8
Fatigue
Interleukin-6
Sleep
Serum
Nurses
Pain
C-Reactive Protein
Leukocytes
Quality of Life
Tartrate-Resistant Acid Phosphatase
Depression
Equipment and Supplies

ASJC Scopus subject areas

  • Oncology
  • Oncology(nursing)

Cite this

The Relationship Between Inflammatory Biomarkers and Symptom Distress in Lung Cancer Patients Undergoing Chemotherapy. / Chou, Hsiu Ling; Chao, Tsu Yi; Chen, Tsan Chi; Chu, Chi Ming; Hsieh, Chen Hsi; Yao, Chung Tay; Janckila, Anthony J.

In: Cancer Nursing, Vol. 40, No. 2, 2017, p. E1-E8.

Research output: Contribution to journalArticle

Chou, Hsiu Ling ; Chao, Tsu Yi ; Chen, Tsan Chi ; Chu, Chi Ming ; Hsieh, Chen Hsi ; Yao, Chung Tay ; Janckila, Anthony J. / The Relationship Between Inflammatory Biomarkers and Symptom Distress in Lung Cancer Patients Undergoing Chemotherapy. In: Cancer Nursing. 2017 ; Vol. 40, No. 2. pp. E1-E8.
@article{648a93aa40c249ad9fec386dad504c68,
title = "The Relationship Between Inflammatory Biomarkers and Symptom Distress in Lung Cancer Patients Undergoing Chemotherapy",
abstract = "BACKGROUND:: Symptom distress often occurs in lung cancer patients undergoing chemotherapy. However, a biomarker has not been identified to reflect the severity of their symptom distress. OBJECTIVE:: The aim of this study was to investigate the relationship between symptom distress and serum inflammatory biomarkers in lung cancer patients undergoing chemotherapy. METHODS:: A longitudinal, repeated-measures design was used to assess subjective symptoms (fatigue, sleep disturbance, pain, depression, and confusion), serum biomarkers (tartrate-resistant acid phosphatase 5a [TRACP5a], interleukin 6 [IL-6], IL-8, and C-reactive protein), and white blood cells in 62 lung cancer patients recruited from a single medical center at 3 time points: T1 was the baseline, T2 was the eighth day after the first chemotherapy cycle, and T3 was prior to the second cycle. Symptom distress was measured individually by 5 questionnaires (General Fatigue Scale, Pittsburgh Sleep Quality Index, Brief Pain Inventory, Profile of Mood States–Depressive, and Confusion). RESULTS:: The trend of TRACP5a was positively correlated to the trend of the patients’ symptom distress. However, the trends of IL-6 and IL-8 did not correlate. CONCLUSIONS:: Serum TRACP5a was associated with symptom distress in lung cancer patients. Therefore, TRACP5a might be a potential biomarker to assess symptom distress of lung cancer patients undergoing chemotherapy. IMPLICATIONS FOR PRACTICE:: Oncology nurses may be able to apply TRACP5a expression to predict or monitor multiple distress symptoms in lung cancer patients undergoing chemotherapy. Furthermore, nurses can use these study findings to better understand the patients who need more attention to improve their quality of life.",
author = "Chou, {Hsiu Ling} and Chao, {Tsu Yi} and Chen, {Tsan Chi} and Chu, {Chi Ming} and Hsieh, {Chen Hsi} and Yao, {Chung Tay} and Janckila, {Anthony J.}",
year = "2017",
doi = "10.1097/NCC.0000000000000369",
language = "English",
volume = "40",
pages = "E1--E8",
journal = "Cancer Nursing",
issn = "0162-220X",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

TY - JOUR

T1 - The Relationship Between Inflammatory Biomarkers and Symptom Distress in Lung Cancer Patients Undergoing Chemotherapy

AU - Chou, Hsiu Ling

AU - Chao, Tsu Yi

AU - Chen, Tsan Chi

AU - Chu, Chi Ming

AU - Hsieh, Chen Hsi

AU - Yao, Chung Tay

AU - Janckila, Anthony J.

PY - 2017

Y1 - 2017

N2 - BACKGROUND:: Symptom distress often occurs in lung cancer patients undergoing chemotherapy. However, a biomarker has not been identified to reflect the severity of their symptom distress. OBJECTIVE:: The aim of this study was to investigate the relationship between symptom distress and serum inflammatory biomarkers in lung cancer patients undergoing chemotherapy. METHODS:: A longitudinal, repeated-measures design was used to assess subjective symptoms (fatigue, sleep disturbance, pain, depression, and confusion), serum biomarkers (tartrate-resistant acid phosphatase 5a [TRACP5a], interleukin 6 [IL-6], IL-8, and C-reactive protein), and white blood cells in 62 lung cancer patients recruited from a single medical center at 3 time points: T1 was the baseline, T2 was the eighth day after the first chemotherapy cycle, and T3 was prior to the second cycle. Symptom distress was measured individually by 5 questionnaires (General Fatigue Scale, Pittsburgh Sleep Quality Index, Brief Pain Inventory, Profile of Mood States–Depressive, and Confusion). RESULTS:: The trend of TRACP5a was positively correlated to the trend of the patients’ symptom distress. However, the trends of IL-6 and IL-8 did not correlate. CONCLUSIONS:: Serum TRACP5a was associated with symptom distress in lung cancer patients. Therefore, TRACP5a might be a potential biomarker to assess symptom distress of lung cancer patients undergoing chemotherapy. IMPLICATIONS FOR PRACTICE:: Oncology nurses may be able to apply TRACP5a expression to predict or monitor multiple distress symptoms in lung cancer patients undergoing chemotherapy. Furthermore, nurses can use these study findings to better understand the patients who need more attention to improve their quality of life.

AB - BACKGROUND:: Symptom distress often occurs in lung cancer patients undergoing chemotherapy. However, a biomarker has not been identified to reflect the severity of their symptom distress. OBJECTIVE:: The aim of this study was to investigate the relationship between symptom distress and serum inflammatory biomarkers in lung cancer patients undergoing chemotherapy. METHODS:: A longitudinal, repeated-measures design was used to assess subjective symptoms (fatigue, sleep disturbance, pain, depression, and confusion), serum biomarkers (tartrate-resistant acid phosphatase 5a [TRACP5a], interleukin 6 [IL-6], IL-8, and C-reactive protein), and white blood cells in 62 lung cancer patients recruited from a single medical center at 3 time points: T1 was the baseline, T2 was the eighth day after the first chemotherapy cycle, and T3 was prior to the second cycle. Symptom distress was measured individually by 5 questionnaires (General Fatigue Scale, Pittsburgh Sleep Quality Index, Brief Pain Inventory, Profile of Mood States–Depressive, and Confusion). RESULTS:: The trend of TRACP5a was positively correlated to the trend of the patients’ symptom distress. However, the trends of IL-6 and IL-8 did not correlate. CONCLUSIONS:: Serum TRACP5a was associated with symptom distress in lung cancer patients. Therefore, TRACP5a might be a potential biomarker to assess symptom distress of lung cancer patients undergoing chemotherapy. IMPLICATIONS FOR PRACTICE:: Oncology nurses may be able to apply TRACP5a expression to predict or monitor multiple distress symptoms in lung cancer patients undergoing chemotherapy. Furthermore, nurses can use these study findings to better understand the patients who need more attention to improve their quality of life.

UR - http://www.scopus.com/inward/record.url?scp=84962077653&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84962077653&partnerID=8YFLogxK

U2 - 10.1097/NCC.0000000000000369

DO - 10.1097/NCC.0000000000000369

M3 - Article

C2 - 27044062

AN - SCOPUS:84962077653

VL - 40

SP - E1-E8

JO - Cancer Nursing

JF - Cancer Nursing

SN - 0162-220X

IS - 2

ER -